Wuxi Biologics (Cayman) Inc. (HK:2269)
:2269
Want to see HK:2269 full AI Analyst Report?
2269 Stock Chart & Stats
HK$35.72
HK$0.44(2.67%)
At close: 4:00 PM EST
HK$35.72
HK$0.44(2.67%)
Day’s Range― - ―
52-Week RangeHK$23.10 - HK$44.00
Previous CloseN/A
Volume35.71M
Average Volume (3M)32.67M
Market Cap
HK$123.98B
Enterprise ValueHK$113.09B
Total Cash (Recent Filing)HK$15.74B
Total Debt (Recent Filing)HK$3.11B
Price to Earnings (P/E)22.2
Beta1.78
Next Earnings
Aug 26, 2026EPS Estimate
0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.19
Shares Outstanding4,141,014,600
10 Day Avg. Volume33,789,006
30 Day Avg. Volume32,668,415
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)2.53
Price to Sales (P/S)5.48
P/FCF Ratio42.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$45.32Price Target Upside26.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)1.33
Revenue Forecast (FY)HK$25.24B
Bulls Say, Bears Say
Bulls Say
High Profitability / MarginsSustained high gross and operating margins provide structural earnings resilience and internal funding for R&D and capacity expansion. These margins support durable cash generation across business cycles and give pricing and contract negotiation leverage with biopharma clients over the next 2–6 months and beyond.
Conservative Balance Sheet / Low LeverageVery low leverage reduces refinancing and solvency risk and preserves optionality for capex or strategic M&A to add capacity. This balance sheet strength underpins long-term operational flexibility and lowers financial distress risk as the company scales manufacturing capacity.
Integrated CRDMO Platform / Client StickinessAn end-to-end service offering increases client stickiness and program lifetime value because customers prefer consolidated vendors for CMC and commercial supply. That structural advantage drives more recurring, higher-margin manufacturing contracts as client programs advance.
Bears Say
Slowing Revenue GrowthA marked deceleration in top-line growth weakens visibility into capacity utilization and future margin expansion. If client program additions stall or commercialization timelines slip, the company may face underused capacity and pressure on long-term revenue trajectory over the next several quarters.
Subpar Cash Conversion & FCF VolatilityDespite recent positive FCF, cash conversion remains well below accounting earnings and has been volatile historically. This limits internal funding for large capacity projects and increases dependence on external financing for growth, raising execution risk for multi-year expansion plans.
Returns Below Prior Peak / NormalizationROE and margins appear to have normalized below peak levels, suggesting either mix shifts or higher cost base versus earlier years. Persistently lower returns can constrain reinvestment efficiency and shareholder value creation if not reversed by higher growth or margin recovery.
Wuxi Biologics (Cayman) News
2269 FAQ
What was Wuxi Biologics (Cayman) Inc.’s price range in the past 12 months?
Wuxi Biologics (Cayman) Inc. lowest stock price was HK$23.10 and its highest was HK$44.00 in the past 12 months.
What is Wuxi Biologics (Cayman) Inc.’s market cap?
Wuxi Biologics (Cayman) Inc.’s market cap is HK$123.98B.
When is Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date?
Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date is Aug 26, 2026 which is in 75 days.
How were Wuxi Biologics (Cayman) Inc.’s earnings last quarter?
Wuxi Biologics (Cayman) Inc. released its earnings results on Mar 24, 2026. The company reported HK$0.68 earnings per share for the quarter, missing the consensus estimate of HK$0.725 by -HK$0.045.
Is Wuxi Biologics (Cayman) Inc. overvalued?
According to Wall Street analysts Wuxi Biologics (Cayman) Inc.’s price is currently Undervalued.
Does Wuxi Biologics (Cayman) Inc. pay dividends?
Wuxi Biologics (Cayman) Inc. does not currently pay dividends.
What is Wuxi Biologics (Cayman) Inc.’s EPS estimate?
Wuxi Biologics (Cayman) Inc.’s EPS estimate is 0.68.
How many shares outstanding does Wuxi Biologics (Cayman) Inc. have?
Wuxi Biologics (Cayman) Inc. has 4,141,014,600 shares outstanding.
What happened to Wuxi Biologics (Cayman) Inc.’s price movement after its last earnings report?
Wuxi Biologics (Cayman) Inc. reported an EPS of HK$0.68 in its last earnings report, missing expectations of HK$0.725. Following the earnings report the stock price went up 4.568%.
Which hedge fund is a major shareholder of Wuxi Biologics (Cayman) Inc.?
Currently, no hedge funds are holding shares in HK:2269
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Wuxi Biologics (Cayman) Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$45.32 (26.89% Upside)
HK$45.32 (26.89% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
120.16%
12-Months-Change
Fundamentals
Return on Equity
10.64%
Trailing 12-Months
Asset Growth
16.77%
Trailing 12-Months
Company Description
Wuxi Biologics (Cayman) Inc.
Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.
2269 Company Deck
2269 Earnings Call
Q4 2026
0:00 / 0:00
2269 Stock 12 Month Forecast
Average Price Target
HK$45.32
▲(26.89% Upside)
Technical Analysis
Genscript Biotech
―
Pharmaron Beijing Co., Ltd. Class H
―
Frontage Holdings Corp.
―
Viva Biotech Holdings
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Options Prices
Currently, No data available
---